Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year survival rate of merely 49.1%. The clinical management of H…